This study is exploring if oxytocin nasal spray, when given with oxycodone (an opioid pain medication), can reduce oxycodone's potential for abuse and improve its pain-relieving effects. Researchers will give participants different combinations of oxycodone (5 mg or 2.5 mg oral tablets) and oxytocin nasal spray (48 IU), or placebos (inactive substances), to see how they affect pain and other responses. You might be eligible if you are between 21 and 45 years old, use opioids recreationally, are in good general health, and do not have chronic pain. The main goal is to understand how oxytocin affects the likelihood of oxycodone abuse. The study plans to enroll 45 participants, but its current status is unclear.

Study design

This is a double-blind, randomized, placebo-controlled study where participants will receive different treatments across multiple sessions. It involves 45 participants and is designed to compare the effects of oxytocin and oxycodone, both alone and in combination.

What's involved

You would participate in a 6-session laboratory study. This includes a medical history review, a screening session, and self-administering intranasal oxytocin or placebo shortly after oral oxycodone or placebo.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, subject-rated abuse liability, will be measured at up to 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.